Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 2271 entries
Sorted by: Best Match Show Resources per page
Comparative effectiveness of liraglutide in the treatment of type 2 diabetes.

Diabetes, metabolic syndrome and obesity : targets and therapy

Rigato M, Fadini GP.
PMID: 24672252
Diabetes Metab Syndr Obes. 2014 Mar 18;7:107-20. doi: 10.2147/DMSO.S37644. eCollection 2014.

Type 2 diabetes is characterized by a progressive decline in beta cell function, with consequent worsening of glycemic control. The ideal antihyperglycemic treatment should achieve good and sustained glycemic control, with a low risk of hypoglycemia and no weight...

Cite
Rigato M, Fadini GP. Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2014;7:107-20doi: 10.2147/DMSO.S37644.
Rigato, M., & Fadini, G. P. (2014). Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy, 7107-20. https://doi.org/10.2147/DMSO.S37644
Rigato, Mauro, and Fadini, Gian Paolo. "Comparative effectiveness of liraglutide in the treatment of type 2 diabetes." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 7 (2014): 107-20. doi: https://doi.org/10.2147/DMSO.S37644
Rigato M, Fadini GP. Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2014 Mar 18;7:107-20. doi: 10.2147/DMSO.S37644. eCollection 2014. PMID: 24672252; PMCID: PMC3964023.
Copy Download .nbib Format: NLM
Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1.

International journal of endocrinology

Wang X, Liu H, Chen J, Li Y, Qu S.
PMID: 26366173
Int J Endocrinol. 2015;2015:651757. doi: 10.1155/2015/651757. Epub 2015 Aug 20.

The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels. It also improves beta-cell proliferation and prevents beta-cell...

Cite
Wang X, Liu H, Chen J, et al. Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1. Int J Endocrinol. 2015;2015:651757doi: 10.1155/2015/651757.
Wang, X., Liu, H., Chen, J., Li, Y., & Qu, S. (2015). Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1. International journal of endocrinology, 2015651757. https://doi.org/10.1155/2015/651757
Wang, XingChun, et al. "Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1." International journal of endocrinology vol. 2015 (2015): 651757. doi: https://doi.org/10.1155/2015/651757
Wang X, Liu H, Chen J, Li Y, Qu S. Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1. Int J Endocrinol. 2015;2015:651757. doi: 10.1155/2015/651757. Epub 2015 Aug 20. PMID: 26366173; PMCID: PMC4558455.
Copy Download .nbib Format: NLM
Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine.

Oncology letters

Song Y, Zhou M, Cao Y, Qi J, Geng J, Liu X.
PMID: 28454451
Oncol Lett. 2017 Apr;13(4):2684-2690. doi: 10.3892/ol.2017.5752. Epub 2017 Feb 20.

Recent reports have demonstrated that long-term and high dosage treatments with incretin-based medicine, such as hormone glucagon-like peptide-1 (GLP-1) may induce thyroid C-cell pathological changes in rodents, rather than in humans. Doubts regarding the tumorigenic potential of GLP-1 analogues...

Cite
Song Y, Zhou M, Cao Y, et al. Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine. Oncol Lett. 2017;13(4):2684-2690doi: 10.3892/ol.2017.5752.
Song, Y., Zhou, M., Cao, Y., Qi, J., Geng, J., & Liu, X. (2017). Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine. Oncology letters, 13(4), 2684-2690. https://doi.org/10.3892/ol.2017.5752
Song, Yuejia, et al. "Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine." Oncology letters vol. 13,4 (2017): 2684-2690. doi: https://doi.org/10.3892/ol.2017.5752
Song Y, Zhou M, Cao Y, Qi J, Geng J, Liu X. Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine. Oncol Lett. 2017 Apr;13(4):2684-2690. doi: 10.3892/ol.2017.5752. Epub 2017 Feb 20. PMID: 28454451; PMCID: PMC5403711.
Copy Download .nbib Format: NLM
Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2.

Diabetology & metabolic syndrome

Valerio CM, de Almeida JS, Moreira RO, Aguiar LBS, Siciliano PO, Carvalho DP, Godoy-Matos AF.
PMID: 28450900
Diabetol Metab Syndr. 2017 Apr 24;9:26. doi: 10.1186/s13098-017-0226-0. eCollection 2017.

BACKGROUND: Dipeptidyl peptidase-4 (DDP4) is an enzyme responsible for glucagon-like peptide-1 inactivation and plays an important role in glucose metabolism.OBJECTIVE: The aim of this study was to evaluate DPP4 levels in patients with familial partial lipodystrophy type 2 (FPLD2)...

Cite
Valerio CM, de Almeida JS, Moreira RO, et al. Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2. Diabetol Metab Syndr. 2017;9:26doi: 10.1186/s13098-017-0226-0.
Valerio, C. M., de Almeida, J. S., Moreira, R. O., Aguiar, L. B. S., Siciliano, P. O., Carvalho, D. P., & Godoy-Matos, A. F. (2017). Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2. Diabetology & metabolic syndrome, 926. https://doi.org/10.1186/s13098-017-0226-0
Valerio, Cynthia Melissa, et al. "Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2." Diabetology & metabolic syndrome vol. 9 (2017): 26. doi: https://doi.org/10.1186/s13098-017-0226-0
Valerio CM, de Almeida JS, Moreira RO, Aguiar LBS, Siciliano PO, Carvalho DP, Godoy-Matos AF. Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2. Diabetol Metab Syndr. 2017 Apr 24;9:26. doi: 10.1186/s13098-017-0226-0. eCollection 2017. PMID: 28450900; PMCID: PMC5404683.
Copy Download .nbib Format: NLM
WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.

Canadian journal of diabetes

Lovshin JA.
PMID: 28392300
Can J Diabetes. 2017 Apr 05; doi: 10.1016/j.jcjd.2017.02.003. Epub 2017 Apr 05.

The Publisher regrets that this article is an accidental duplication of an article that has already been published, http://dx.doi.org/10.1016/j.jcjd.2017.02.003. The duplicate article has therefore been withdrawn. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.

Cite
Lovshin JA. WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. Can J Diabetes. 2017;doi: 10.1016/j.jcjd.2017.02.003.
Lovshin, J. A. (2017). WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. Canadian journal of diabetes, . https://doi.org/10.1016/j.jcjd.2017.02.003
Lovshin, Julie A. "WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes." Canadian journal of diabetes vol. (2017). doi: https://doi.org/10.1016/j.jcjd.2017.02.003
Lovshin JA. WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. Can J Diabetes. 2017 Apr 05; doi: 10.1016/j.jcjd.2017.02.003. Epub 2017 Apr 05. PMID: 28392300.
Copy Download .nbib Format: NLM
Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study.

Journal of diabetes investigation

Nino A, Okuda I, Wilson TH, Yue L, Nakajima H, Tsuboi M, Carr MC, Seino Y.
PMID: 28921915
J Diabetes Investig. 2017 Sep 16; doi: 10.1111/jdi.12749. Epub 2017 Sep 16.

AIMS/INTRODUCTION: The present phase 3, randomized, double-blind 24-week study with extension to 1 year assessed the efficacy and safety of albiglutide compared with placebo in Japanese patients with type 2 diabetes mellitus inadequately controlled by diet and exercise with...

Cite
Nino A, Okuda I, Wilson TH, et al. Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. J Diabetes Investig. 2017;doi: 10.1111/jdi.12749.
Nino, A., Okuda, I., Wilson, T. H., Yue, L., Nakajima, H., Tsuboi, M., Carr, M. C., & Seino, Y. (2017). Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Journal of diabetes investigation, . https://doi.org/10.1111/jdi.12749
Nino, Antonio, et al. "Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study." Journal of diabetes investigation vol. (2017). doi: https://doi.org/10.1111/jdi.12749
Nino A, Okuda I, Wilson TH, Yue L, Nakajima H, Tsuboi M, Carr MC, Seino Y. Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. J Diabetes Investig. 2017 Sep 16; doi: 10.1111/jdi.12749. Epub 2017 Sep 16. PMID: 28921915; PMCID: PMC5934244.
Copy Download .nbib Format: NLM
Liraglutide for weight management: a critical review of the evidence.

Obesity science & practice

Mehta A, Marso SP, Neeland IJ.
PMID: 28392927
Obes Sci Pract. 2017 Mar;3(1):3-14. doi: 10.1002/osp4.84. Epub 2016 Dec 19.

OBJECTIVE: To review the efficacy, safety, and clinical applicability of liraglutide for weight management from phase III clinical trials.METHODS: A search of the English language literature was performed using PubMed search terms: "liraglutide", "glucagon-like peptide-1 receptor agonist", and "randomized...

Cite
Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2016;3(1):3-14doi: 10.1002/osp4.84.
Mehta, A., Marso, S. P., & Neeland, I. J. (2017). Liraglutide for weight management: a critical review of the evidence. Obesity science & practice, 3(1), 3-14. https://doi.org/10.1002/osp4.84
Mehta, A, et al. "Liraglutide for weight management: a critical review of the evidence." Obesity science & practice vol. 3,1 (2017): 3-14. doi: https://doi.org/10.1002/osp4.84
Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017 Mar;3(1):3-14. doi: 10.1002/osp4.84. Epub 2016 Dec 19. PMID: 28392927; PMCID: PMC5358074.
Copy Download .nbib Format: NLM
Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus.

Clinical therapeutics

Milicevic Z.
PMID: 27673601
Clin Ther. 2016 Oct 06;38(10):e1. doi: 10.1016/j.clinthera.2016.07.013.

No abstract available.

Cite
Milicevic Z. Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus. Clin Ther. 2016;38(10):e1doi: 10.1016/j.clinthera.2016.07.013.
Milicevic, Z. (2016). Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus. Clinical therapeutics, 38(10), e1. https://doi.org/10.1016/j.clinthera.2016.07.013
Milicevic, Z. "Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus." Clinical therapeutics vol. 38,10 (2016): e1. doi: https://doi.org/10.1016/j.clinthera.2016.07.013
Milicevic Z. Experience from Development of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Dulaglutide for Treatment of Type 2 Diabetes Mellitus. Clin Ther. 2016 Oct 06;38(10):e1. doi: 10.1016/j.clinthera.2016.07.013. PMID: 27673601.
Copy Download .nbib Format: NLM
Two lessons from the empiric management of a combined overdose of liraglutide and amitriptyline.

A & A case reports

Bowler M, Nethercott DR.
PMID: 25611153
A A Case Rep. 2014 Feb 01;2(3):28-30. doi: 10.1097/ACC.0b013e3182a526fa.

We report the case of a 52-year-old man with a combined liraglutide and amitriptyline overdose who presented with a seizure and then pulseless electrical activity cardiac arrest. This is the largest reported overdose of liraglutide (36 mg), a novel...

Cite
Bowler M, Nethercott DR. Two lessons from the empiric management of a combined overdose of liraglutide and amitriptyline. A A Case Rep. 2014;2(3):28-30doi: 10.1097/ACC.0b013e3182a526fa.
Bowler, M., & Nethercott, D. R. (2014). Two lessons from the empiric management of a combined overdose of liraglutide and amitriptyline. A & A case reports, 2(3), 28-30. https://doi.org/10.1097/ACC.0b013e3182a526fa
Bowler, Matthew, and Nethercott, Daniel Robert. "Two lessons from the empiric management of a combined overdose of liraglutide and amitriptyline." A & A case reports vol. 2,3 (2014): 28-30. doi: https://doi.org/10.1097/ACC.0b013e3182a526fa
Bowler M, Nethercott DR. Two lessons from the empiric management of a combined overdose of liraglutide and amitriptyline. A A Case Rep. 2014 Feb 01;2(3):28-30. doi: 10.1097/ACC.0b013e3182a526fa. PMID: 25611153.
Copy Download .nbib Format: NLM
The Investigation of Plasma Glucagon-like Peptide-1 Levels in Newly Diagnosed Type 1 Diabetic Children.

The West Indian medical journal

Uslu B, Gurbuz F, Temiz F, Yuksel B, Mungan N, Topaloglu AK.
PMID: 26901603
West Indian Med J. 2015 Sep 03;65(1):141-146. doi: 10.7727/wimj.2014.134.

OBJECTIVE: To reveal the possible role of glucagon-like peptide-1 (GLP-1) in newly diagnosed Type 1 diabetic children.METHODS: Twenty-five newly diagnosed children and 22 healthy children were included in the study.RESULTS: In oral glucose tolerance tests, no correlation was observed...

Cite
Uslu B, Gurbuz F, Temiz F, et al. The Investigation of Plasma Glucagon-like Peptide-1 Levels in Newly Diagnosed Type 1 Diabetic Children. West Indian Med J. 2015;65(1):141-146doi: 10.7727/wimj.2014.134.
Uslu, B., Gurbuz, F., Temiz, F., Yuksel, B., Mungan, N., & Topaloglu, A. K. (2015). The Investigation of Plasma Glucagon-like Peptide-1 Levels in Newly Diagnosed Type 1 Diabetic Children. The West Indian medical journal, 65(1), 141-146. https://doi.org/10.7727/wimj.2014.134
Uslu, B, et al. "The Investigation of Plasma Glucagon-like Peptide-1 Levels in Newly Diagnosed Type 1 Diabetic Children." The West Indian medical journal vol. 65,1 (2015): 141-146. doi: https://doi.org/10.7727/wimj.2014.134
Uslu B, Gurbuz F, Temiz F, Yuksel B, Mungan N, Topaloglu AK. The Investigation of Plasma Glucagon-like Peptide-1 Levels in Newly Diagnosed Type 1 Diabetic Children. West Indian Med J. 2015 Sep 03;65(1):141-146. doi: 10.7727/wimj.2014.134. PMID: 26901603.
Copy Download .nbib Format: NLM
Specific appetite, energetic and metabolomics responses to fat overfeeding in resistant-to-bodyweight-gain constitutional thinness.

Nutrition & diabetes

Germain N, Galusca B, Caron-Dorval D, Martin JF, Pujos-Guillot E, Boirie Y, Khalfallah Y, Ling Y, Minnion JS, Bloom SR, Epelbaum J, Estour B.
PMID: 25027794
Nutr Diabetes. 2014 Jul 14;4:e126. doi: 10.1038/nutd.2014.17.

BACKGROUND: Contrasting with obesity, constitutional thinness (CT) is a rare condition of natural low bodyweight. CT exhibits preserved menstruation in females, no biological marker of undernutrition, no eating disorders but a bodyweight gain desire. Anorexigenic hormonal profile with high...

Cite
Germain N, Galusca B, Caron-Dorval D, et al. Specific appetite, energetic and metabolomics responses to fat overfeeding in resistant-to-bodyweight-gain constitutional thinness. Nutr Diabetes. 2014;4:e126doi: 10.1038/nutd.2014.17.
Germain, N., Galusca, B., Caron-Dorval, D., Martin, J. F., Pujos-Guillot, E., Boirie, Y., Khalfallah, Y., Ling, Y., Minnion, J. S., Bloom, S. R., Epelbaum, J., & Estour, B. (2014). Specific appetite, energetic and metabolomics responses to fat overfeeding in resistant-to-bodyweight-gain constitutional thinness. Nutrition & diabetes, 4e126. https://doi.org/10.1038/nutd.2014.17
Germain, N, et al. "Specific appetite, energetic and metabolomics responses to fat overfeeding in resistant-to-bodyweight-gain constitutional thinness." Nutrition & diabetes vol. 4 (2014): e126. doi: https://doi.org/10.1038/nutd.2014.17
Germain N, Galusca B, Caron-Dorval D, Martin JF, Pujos-Guillot E, Boirie Y, Khalfallah Y, Ling Y, Minnion JS, Bloom SR, Epelbaum J, Estour B. Specific appetite, energetic and metabolomics responses to fat overfeeding in resistant-to-bodyweight-gain constitutional thinness. Nutr Diabetes. 2014 Jul 14;4:e126. doi: 10.1038/nutd.2014.17. PMID: 25027794; PMCID: PMC5189928.
Copy Download .nbib Format: NLM
Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1.

Frontiers in immunology

Zietek T, Rath E.
PMID: 27148273
Front Immunol. 2016 Apr 22;7:154. doi: 10.3389/fimmu.2016.00154. eCollection 2016.

Chronic diseases, such as obesity and diabetes, cardiovascular, and inflammatory bowel diseases (IBD) share common features in their pathology. Metabolic disorders exhibit strong inflammatory underpinnings and vice versa, inflammation is associated with metabolic alterations. Next to cytokines and cellular...

Cite
Zietek T, Rath E. Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1. Front Immunol. 2016;7:154doi: 10.3389/fimmu.2016.00154.
Zietek, T., & Rath, E. (2016). Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1. Frontiers in immunology, 7154. https://doi.org/10.3389/fimmu.2016.00154
Zietek, Tamara, and Rath, Eva. "Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1." Frontiers in immunology vol. 7 (2016): 154. doi: https://doi.org/10.3389/fimmu.2016.00154
Zietek T, Rath E. Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1. Front Immunol. 2016 Apr 22;7:154. doi: 10.3389/fimmu.2016.00154. eCollection 2016. PMID: 27148273; PMCID: PMC4840214.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 2271 entries